⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Official Title: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma

Study ID: NCT05233397

Interventions

Tocilizumab

Study Description

Brief Summary: ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.

Detailed Description: Adamantinomatous Craniopharyngioma (ACP) is a highly debilitating pediatric brain tumor that lacks medical anti-tumor therapies. Current therapy, which depends largely on surgery and radiation, is associated with poor quality of life and becomes more challenging and risky in the setting of recurrent disease. Recent discoveries regarding the biological characteristics of ACP indicate that available agents, including IL-6 pathway blockers may have efficacy in the control of ACP. We hypothesize that the IL6- receptor antagonist ACTEMRA (tocilizumab) will be safe and effective at inducing tumor response in children with residual ACP. In this study, up to 38 patients will receive tocilizumab at the dose approved for pediatric Systemic Juvenile Idiopathic Arthritis (\< 30 kg: 12 mg/kg IV every 2 weeks; ≥30 kg: 8 mg/kg IV every 2 weeks). Therapy may continue for up to two years (26 cycles). It will be a multi-center Phase 2 trial with two strata for patients aged \>1 year and \<25 years with unresectable ACP who may have been previously treated with radiation (Stratum 1, 18 patients) or without radiation (Stratum 2, 18 patients).

Keywords

Eligibility

Minimum Age: 1 Year

Eligible Ages: CHILD, ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Children's Hospital Colorado, Aurora, Colorado, United States

Children's National Medical Center, Washington, District of Columbia, United States

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Duke University Health System, Durham, North Carolina, United States

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Nationwide Children's Hospital, Columbus, Ohio, United States

Texas Children's Hospital, Houston, Texas, United States

Seattle Children's Hospital, Seattle, Washington, United States

Sydney Children's Hospital, Randwick, New South Wales, Australia

Queensland Children's Hospital, South Brisbane, Queensland, Australia

Perth Children's Hospital, Perth, Western Australia, Australia

The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada

Montreal Children's Hospital, Montréal, Quebec, Canada

Hopp Children's Cancer Center at NCT Heidelberg (KiTZ), Heidelberg, Baden-Württemberg, Germany

Jasper van der Lugt, Utrecht, , Netherlands

Great Ormond Street Hospital, London, , United Kingdom

Contact Details

Name: Kathleen H Dorris, MD

Affiliation: Children's Hospital Colorado

Role: STUDY_CHAIR

Name: Todd C Hankinson, MD

Affiliation: Children's Hospital Colorado

Role: STUDY_CHAIR

Name: Maryam Fouladi, MD

Affiliation: Nationwide Children's Hospital

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: